Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Women presenting for planned cesarean delivery.

• American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.

• Singleton gestation in the 3rd trimester (28-42 weeks gestation).

• Spinal anesthesia technique Women presenting for planned cesarean delivery.

• American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.

• Singleton gestation in the 3rd trimester (28-42 weeks gestation).

• Spinal anesthesia technique.

Exclusion Criteria:

• Any contraindication to spinal anesthesia technique.

• Allergy or intolerance to dexmedetomidine or clonidine.

• Oral temperature < 36° Celsius prior to procedure.

• Unable to give personal consent.

• PPROM or concern for infection (e.g., chorioamnionitis).

• Conversion to General Anesthesia prior to randomization.

• Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered prior to randomization.